Clinically relevant drug interactions between statins and antidepressants
Caterina Palleria1, Roberta Roberti1, Luigi Francesco Iannone1
1Science of Health Department, School of Medicine, University of Catanzaro, Catanzaro, Italy.
Journal of Clinical Pharmacy and Therapeutics
|October 7, 2019
Summary
Drug interactions between statins and antidepressants are uncommon but require careful consideration. Choosing antidepressants with favorable profiles can minimize potential risks, guiding appropriate medication choices for patients.
Area of Science:
- Pharmacology
- Drug Interactions
- Cardiovascular and Psychiatric Medicine
Background:
- Statins and antidepressants are frequently co-prescribed due to high global rates of cardiovascular and psychiatric disorders.
- Potential pharmacokinetic (PK) and pharmacodynamic (PD) drug-drug interactions (DDIs) between these drug classes are not well-understood.
- Adverse events (AEs) and management strategies for combined statin and antidepressant use require further investigation.
Purpose of the Study:
- To review and describe clinically relevant PK and PD interactions between statins and antidepressants.
- To provide an overview of the pharmacological features of these drug classes for safe co-administration.
- To inform appropriate multiple drug regimens in clinical practice.
Main Methods:
- Literature search of PubMed and Cochrane databases for relevant studies.
- Focus on clinically significant drug-drug interactions (DDIs) between statins and antidepressants.
- Inclusion of English-language publications only.
Main Results:
- Pharmacodynamic (PD) interactions are unlikely due to the high selectivity of statins.
- Limited clinical studies exist; most data on PK interactions are speculative, based on metabolic pathways and transporter data.
- Second-generation antidepressants (e.g., citalopram, escitalopram, mirtazapine, reboxetine, venlafaxine) show weaker CYP inhibition.
- Certain antidepressants (nefazodone, fluoxetine, paroxetine, fluvoxamine) significantly affect CYP activity, potentially altering statin levels.
- Pravastatin, pitavastatin, and rosuvastatin are not susceptible to CYP inhibition.
- Clinically significant P-glycoprotein (P-gp) interactions are unlikely.
Conclusions:
- While potentially clinically significant DDIs are rare, using antidepressants with favorable interaction profiles is recommended.
- Further PK/PD studies are needed to provide clinicians with robust data for managing combined statin-antidepressant therapy.
- This review highlights the need for informed prescribing to optimize patient outcomes.
Related Concept Videos
01:25Antidepressant Drugs: Overview
1.3K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.3K
01:23Antidepressant Drugs: MAOIs and Other Agents
761
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
761
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:25Pharmacokinetics: Drug–Drug Interactions
313
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
313
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
184
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
184